Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Improvements to levodopa-based treatments for Parkinson’s disease

Alberto Espay, MD, MSc, University of Cincinnati, Cincinnati, OH, describes the current efforts to improve levodopa-based treatments for Parkinson’s disease. These new systems include subcutaneous levodopa infusion, subcutaneous foslevodopa infusion, subcutaneous apomorphine infusion, and an oral extended-release carbidopa-levodopa – IPX203.
Experts believe that these new approaches will extend the duration of time that these treatments are effective for. IPX203 is due for FDA review in June 2023. The subcutaneous infusions will take longer for approval but may be approved within a year. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Amneal, Acadia, Avion Pharmaceuticals, Acorda, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), and Herantis Pharma; personal honoraria for speakership for Avion, Amneal, and Supernus; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics and is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He serves on the editorial boards of the Journal of Parkinson’s Disease, Journal of Alzheimer’s Disease, European Journal of Neurology, Movement Disorders Clinical Practice, and JAMA Neurology.